StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

Seres Therapeutics (NASDAQ:MCRB) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

MCRB has been the topic of a number of other research reports. The Goldman Sachs Group cut their target price on Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating on the stock in a research note on Friday, March 14th. Chardan Capital restated a “neutral” rating and issued a $6.00 price objective (up previously from $1.25) on shares of Seres Therapeutics in a research note on Thursday. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Seres Therapeutics presently has an average rating of “Hold” and an average target price of $75.25.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $6.98 on Friday. The company has a market cap of $60.81 million, a P/E ratio of -30.32 and a beta of 2.89. Seres Therapeutics has a fifty-two week low of $6.90 and a fifty-two week high of $30.60. The stock has a 50 day simple moving average of $11.80 and a two-hundred day simple moving average of $14.72.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($1.57). On average, research analysts predict that Seres Therapeutics will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Seres Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Vontobel Holding Ltd. boosted its stake in Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 543,469 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 117,107 shares during the period. Geode Capital Management LLC grew its stake in Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after acquiring an additional 255,014 shares in the last quarter. Avantax Advisory Services Inc. boosted its holdings in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the period. Finally, Virtu Financial LLC grew its position in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.